Regeneron
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
CEOLeonard S. Schleifer
CEOLeonard S. Schleifer
Employees13,450
Employees13,450
HeadquartersTarrytown, New York
HeadquartersTarrytown, New York
Founded1988
Founded1988
Employees13,450
Employees13,450
REGN Key Statistics
Market cap74.89B
Market cap74.89B
Price-Earnings ratio16.87
Price-Earnings ratio16.87
Dividend yield—
Dividend yield—
Average volume910.15K
Average volume910.15K
High today$707.48
High today$707.48
Low today$681.13
Low today$681.13
Open price$704.17
Open price$704.17
Volume1.11M
Volume1.11M
52 Week high$1,211.20
52 Week high$1,211.20
52 Week low$666.25
52 Week low$666.25
REGN News
TipRanks 3d
Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiationsWelcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the Market: Discover outperforming...
Fortune 4d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers - Fortune...
TipRanks 5d
Regeneron downgraded to Neutral from Buy at UBSUBS downgraded Regeneron (REGN) to Neutral from Buy with a price target of $738, down from $1,130. The firm believes there is a disconnect between the market’s...
Analyst ratings
62%
of 29 ratingsBuy
62.1%
Hold
34.5%
Sell
3.4%
More REGN News
Benzinga 6d
Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030Regeneron Pharmaceuticals Inc. REGN CEO and founder Leonard Schleifer highlighted the company’s product pipeline during JPMorgan’s Healthcare Conference on Mond...
